Immune thrombocytopenia (ITP) has seen the development and evaluation of several breakthroughs in recent clinical trials [1-4]. The clinical trial landscape for ITP provides valuable insights into current treatment strategies, research trends, and future directions. On July 3, 2024, a search of the Informa Database identified a limited total of 339 trials for ITP, suggesting a significant research gap that needs addressing.
